InMed Pharmaceuticals
7 hedge funds and large institutions have $241K invested in InMed Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 4 closing their positions.
7.07% less ownership
Funds ownership: 15.16% → 8.1% (-7.1%)
22% less funds holding
Funds holding: 9 → 7 (-2)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
64% less capital invested
Capital invested by funds: $665K → $241K (-$425K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$21.2K |
| 2 |
Jane Street
New York
|
+$19.9K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$626 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
-$78.5K |
| 2 |
VF
Virtu Financial
New York
|
-$45K |
| 3 |
Renaissance Technologies
New York
|
-$36.8K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$30.5K |
| 5 |
TDC
Thompson Davis & Co
Richmond,
Virginia
|
-$22.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $214K | -$30.5K | -18,365 | -8% |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $13.5K | +$21.2K | +12,753 | New |
|
|
3
Jane Street
New York
| $12.7K | +$19.9K | +11,978 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $400 | +$626 | +377 | New |
|
|
SS
5
SBI Securities
Tokyo,
Japan
| $318 | – | – | – |
|
|
FDCDDQ
6
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $2 | – | – | – |
|
|
DS
7
DRW Securities
Chicago,
Illinois
| – | -$78.5K | -35,865 | Closed |
|
|
VF
8
Virtu Financial
New York
| – | -$45K | -20,369 | Closed |
|
|
9
Renaissance Technologies
New York
| – | -$36.8K | -16,800 | Closed |
|
|
TDC
10
Thompson Davis & Co
Richmond,
Virginia
| – | -$22.4K | -10,249 | Closed |
|
INM Hedge Fund Activity: Q4 2025 in Review
7 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in InMed Pharmaceuticals (INM) for Q4 2025, worth a combined $241K — down 64% from $665K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of INM and 3 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $21.2K. The largest seller was DRW Securities, exiting entirely with an estimated $78.5K sold.
- 7 institutional investors held InMed Pharmaceuticals (INM) as of Q4 2025, down from 9 in Q3 2025.
- Funds reported $241K of InMed Pharmaceuticals stock for Q4 2025, down 64% quarter-over-quarter.
- 3 funds opened new InMed Pharmaceuticals positions in Q4 2025 and 4 closed out, a net change of -1 holder.
- The largest InMed Pharmaceuticals buyer in Q4 2025 was Susquehanna International Group, an estimated $21.2K added.
- The largest InMed Pharmaceuticals seller in Q4 2025 was DRW Securities, an estimated $78.5K sold.
Based on aggregated 13F filings for Q4 2025.